Optimize Value in a Complex Pricing and Access Environment
The pace of innovation in biopharmaceuticals is rapid and the impact on human health has been profound. The most successful companies have robust R&D and commercial capabilities to thrive in an increasingly value-based health care environment. BHA supports biopharma innovators where value is only emerging– precision medicines and high value specialty and orphan drugs. BHA supports companies in making critical business decisions during this exciting—and unprecedented—time for a global industry poised to deliver outcomes that create proven value for patients.
Optimize Value in a Complex Pricing and Access Environment
The pace of innovation in biopharmaceuticals is rapid and the impact on human health has been profound. The most successful companies have robust R&D and commercial capabilities to thrive in an increasingly value-based health care environment. BHA supports biopharma innovators where value is only emerging– precision medicines and high value specialty and orphan drugs. BHA supports companies in making critical business decisions during this exciting—and unprecedented—time for a global industry poised to deliver outcomes that create proven value for patients.
Focus Areas
- Precision Medicines
- Specialty Drugs
- Orphan Drugs
- Cell and Gene Therapy
- 505(b)2 Approval Pathway
Solutions
- Companion Diagnostics Global Commercialization Roadmap
- Pricing Strategy
- Market Opportunity Assessment
- Evidence Development Strategy
- Health Economic Analysis
Therapeutic Areas
- Hematology | Oncology
- Pain | CNS | Neuromuscular | Neurologic Disorders
- Immune Disorders | Inflammation
- Cardiovascular Disease
- Enzyme Deficiency Disorders
- Gastrointestinal | Hepatic Disease
- Renal/Metabolic | Endocrine
- Infectious Disease
- Cell and Gene Therapies
Case Studies
Global Market Access Strategy for Companion Diagnostic Test
Health Economic Analysis and Publication Support for Specialty Drug
Market Opportunity Assessment for Orphan Drug in Rare Ocular Malignancy
Transaction Preparation: Novel Biopharmaceutical Planning U.S. Market Entry
